EGFR and neoplasm: In this patient, EGFR-directed therapy and immune checkpoint inhibition during anti-PD-1 therapy with nivolumab prevented tumour progression for 7 and 5 months, respectively (preliminary data, Westphal et al., Manuscript in preparation).